Vivani Medical (VANI)
Develops subdermal implants designed for extended, steady drug delivery.
$1.44
At close+0.07 (+5.51%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | |
| Research & development | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 4 | 4 |
| 3 | 1 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | |
| General & administrative | 3 | 0 | 3 | 2 | 2 | 0 | 2 | 3 | 2 | 2 | 2 | 2 |
| Operating income | −7 | −6 | −6 | −6 | −6 | −6 | −7 | −7 | −7 | −7 | −7 | −7 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Income before tax | −7 | −6 | −6 | −5 | −6 | −6 | −6 | −7 | −7 | −7 | −7 | −6 |
| Net income from continuing operations | −7 | −6 | −6 | −5 | −6 | −6 | −6 | −7 | −7 | −7 | −7 | −6 |
| Net income | −7 | −6 | −6 | −5 | −6 | −6 | −6 | −7 | −7 | −7 | −7 | −6 |
| EPS, basic | −$0.13 | −$0.12 | −$0.12 | −$0.10 | −$0.11 | −$0.11 | −$0.11 | −$0.12 | −$0.11 | −$0.09 | −$0.08 | −$0.07 |
| EPS, diluted | −$0.13 | −$0.12 | −$0.12 | −$0.10 | −$0.11 | −$0.11 | −$0.11 | −$0.12 | −$0.11 | −$0.09 | −$0.08 | −$0.07 |
| Weighted average shares, basic | 51 | 51 | 52 | 55 | 55 | 57 | 59 | 59 | 60 | 62 | 81 | 87 |
| Weighted average shares, diluted | 51 | 51 | 52 | 55 | 55 | 57 | 59 | 59 | 60 | 62 | 81 | 87 |
| EBITDA | −7 | −6 | −6 | −5 | −6 | −6 | −6 | −7 | −6 | −7 | −7 | −7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −7 | −6 | −6 | −5 | −6 | −6 | −6 | −7 | −7 | −7 | −7 | −7 |